CRDF רווח צפוי cardiffoncology.com

לוגו תאגידי של חברת Cardiff Oncology Corp (CRDF)

Cardiff Oncology, Inc. (CRDF) margins depend on the success of clinical trials and cash availability. The forward profitability trend visualizes these expectations, while captures a new level mark. Fierce competition with corporate behemoths over patents creates pressure, and the high cost of current research leads to a rapid depletion of the company's liquid reserves.

CRDF - הכנסה נקייה צפויה Cardiff Oncology Corp בטווח 04.07.2022 - 18.11.2026

פילוחים אנליטיים של חברת Cardiff Oncology Inc. (CRDF)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח מקיף של החברה:CRDF, Cardiff Oncology, Inc.
מוצר עיקרי של Cardiff Oncology

Cardiff Oncology, Inc. (CRDF) is strengthening its position in targeted cancer therapy by developing an innovative PLK1 inhibitor to enhance standard treatment protocols. This chart of expected financial results compares market capitalization with actual business scale, reflecting the real-time investor consensus forecast and allowing for an assessment of the company's fundamental potential without the delays of traditional reporting.